Clinical trial registry record

ALSENLITE: Senolytics for Alzheimer's Disease

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Active Not Recruiting.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated July 17, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04785300
Last registry update
July 17, 2026
Status
Active Not Recruiting
Phase
Phase 1, Phase 2
Enrollment
20
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
INTERVENTIONAL
Evidence population
Human clinical study registration
Participants
20
Population
Not reported
Duration
Not reported
Intervention
Dasatinib; Quercetin
Comparator
Not reported
Outcomes measured
Not reported
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. It cannot show whether an intervention worked or was safe.

Safety and approvalNot reported Not reported

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Senolytics · 60%Title contains controlled term: senolytic. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

senolytics
Read the original source →

Explore metadata mentions

Literal discovery links; no benefit or clinical relevance assessment.